AZ COMPLETES AGREEMENT WITH PERRIGO
15 déc. 2015 10h16 HE
|
AstraZeneca PLC
ASTRAZENECA COMPLETES AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US
AstraZeneca today announced that it has completed its agreement with Perrigo
Company plc for the divestment of US rights...
Discussions with Acerta Pharma BV
14 déc. 2015 03h07 HE
|
AstraZeneca PLC
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS
OF SUCH JURISDICTION. THIS ANNOUNCEMENT...
ASTRAZENECA PLC ANNOUNCES LATE-STAGE PIPELINE CONFERENCE CALL FOR INVESTORS AND ANALYSTS
02 déc. 2015 02h00 HE
|
AstraZeneca PLC
AstraZeneca PLC ("AstraZeneca", "the Company") will today host a conference call
for investors and analysts. This will focus on key potential medicines within
the late-stage pipeline and will provide...
AZ enters agreement w/ Perrigo for Entocort in US
23 nov. 2015 02h00 HE
|
AstraZeneca PLC
ASTRAZENECA ENTERS INTO AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US
Divestment further sharpens focus on three main therapy areas
Agreement follows ex-US divestment of Entocort in...
AZD9291 Approved by the US FDA
13 nov. 2015 10h21 HE
|
AstraZeneca PLC
TAGRISSO™ (AZD9291) APPROVED BY THE US FDA FOR patients with EGFR T790M mutation
-positive METASTATIC non-small cell lung cancer
One of fastest development programmes - from start of clinical trials...
ASTRAZENECA PRICES A $6 BILLION BOND ISSUE
11 nov. 2015 02h30 HE
|
AstraZeneca PLC
AstraZeneca PLC announces that yesterday it conducted a global bond market
transaction by issuing a total of $6bn of notes. The proceeds of the issue will
be used to fund the previously announced...
3rd Quarter Results
10 nov. 2015 02h40 HE
|
AstraZeneca PLC
5 November 2015
Year-To-Date and Q3 2015 Results
Financial Summary
YTD 2015 Q3 2015
$m % change $m % change
...
ASTRAZENECA STRENGTHENS CARDIOVASCULAR AND METABOLIC DISEASE PORTFOLIO WITH ACQUISITION OF ZS PHARMA
06 nov. 2015 06h21 HE
|
AstraZeneca PLC
AstraZeneca to acquire ZS Pharma for $90 per share
Acquisition includes potential best-in-class hyperkalaemia treatment currently
under US FDA regulatory review
Acquisition expected to contribute...
Delårsrapport AstraZeneca PLC för de första nio månaderna och tredje kvartalet 2015
05 nov. 2015 02h03 HE
|
AstraZeneca PLC
Utvecklingen i sammandrag
+----------------------+--------+------+---------++--------+------+-------+
| |Första nio månaderna 2015|| Tredje kvartalet 2015...
AstraZeneca PLC year-to-date and Q3 Results 2015
04 nov. 2015 04h00 HE
|
AstraZeneca PLC
Tomorrow, Thursday, 5th November 2015, AstraZeneca PLC will release year-to-date
and Q3 results for 2015 at 07:00 GMT.
An analyst presentation of the year to date and Q3 results for 2015 will...